Analysis of the key themes driving M&A activity reveals that microbiome accounted for 3 pharmaceutical deals announced in Q4 2023, worth a total value of $511.6m. The $509.3m acquisition of T3 Pharmaceuticals by Boehringer Ingelheim was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, microbiome-related deal activity decreased by % in Q4 2023 compared with the previous quarter’s total of 0 and rose by 4199% as compared to Q4 2022. Related deal volume remained flat in Q4 2023 versus the previous quarter and was 50% higher than in Q4 2022.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.